YntraDose
Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (uLA-PDAC)
Key Facts
About BetaGlue Therapeutics
BetaGlue Therapeutics is a clinical-stage radiopharmaceutical company developing YntraDose, a novel Yttrium-90 microsphere-based radiotherapy platform for the localized treatment of solid tumors. The company is initially targeting difficult-to-treat cancers like unresectable locally advanced pancreatic cancer (uLA-PDAC), with active clinical trials underway in Europe. Led by an experienced team with backgrounds in biotech, medtech, and nuclear medicine, BetaGlue aims to establish a new, more accessible standard of care in interventional oncology by combining biotechnology, nuclear science, and minimally invasive procedures.
View full company profileAbout BetaGlue Therapeutics
BetaGlue Therapeutics is a clinical-stage radiopharmaceutical company developing YntraDose, a novel Yttrium-90 microsphere-based radiotherapy platform for the localized treatment of solid tumors. The company is initially targeting difficult-to-treat cancers like unresectable locally advanced pancreatic cancer (uLA-PDAC), with active clinical trials underway in Europe. Led by an experienced team with backgrounds in biotech, medtech, and nuclear medicine, BetaGlue aims to establish a new, more accessible standard of care in interventional oncology by combining biotechnology, nuclear science, and minimally invasive procedures.
View full company profileAbout BetaGlue Therapeutics
BetaGlue Therapeutics is a clinical-stage radiopharmaceutical company developing YntraDose, a novel Yttrium-90 microsphere-based radiotherapy platform for the localized treatment of solid tumors. The company is initially targeting difficult-to-treat cancers like unresectable locally advanced pancreatic cancer (uLA-PDAC), with active clinical trials underway in Europe. Led by an experienced team with backgrounds in biotech, medtech, and nuclear medicine, BetaGlue aims to establish a new, more accessible standard of care in interventional oncology by combining biotechnology, nuclear science, and minimally invasive procedures.
View full company profile